Importantly, the knockdown of LGR5 increases the sensitivity of adenoma cells to the EGFR inhibitor gefitinib, suggesting low LGR5 expression could be used clinically to predict patients who may benefit from EGFR therapies. Here, EGFR is linked to adenoma.